Tiziana Life Sciences’ (TILS) “Speculative Buy” Rating Reaffirmed at Beaufort Securities
Tiziana Life Sciences PLC (LON:TILS)‘s stock had its “speculative buy” rating reissued by analysts at Beaufort Securities in a note issued to investors on Tuesday. They currently have a GBX 400 ($5.33) target price on the biotechnology company’s stock. Beaufort Securities’ price objective would suggest a potential upside of 158.27% from the stock’s current price.
Shares of Tiziana Life Sciences (TILS) opened at GBX 154.88 ($2.06) on Tuesday. Tiziana Life Sciences has a 1 year low of GBX 102.06 ($1.36) and a 1 year high of GBX 240 ($3.20).
Tiziana Life Sciences (LON:TILS) last released its quarterly earnings results on Friday, September 29th. The biotechnology company reported GBX (4.10) (($0.05)) earnings per share for the quarter, missing the Zacks’ consensus estimate of GBX (2) (($0.03)) by GBX (2.10) (($0.03)).
ILLEGAL ACTIVITY NOTICE: “Tiziana Life Sciences’ (TILS) “Speculative Buy” Rating Reaffirmed at Beaufort Securities” was published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/tiziana-life-sciences-tils-speculative-buy-rating-reaffirmed-at-beaufort-securities/1730111.html.
Tiziana Life Sciences Company Profile
Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its products in clinical stage include Milciclib and Foralumab. Its products in pre-clinical stage include TZLS-101 and TZLS-214.
Receive News & Ratings for Tiziana Life Sciences PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.